Filing Flows › Kymera Therapeutics (KYMR) › Q1 2026 › vs Q4 2025
Kymera Therapeutics (KYMR) Q1 2026 vs Q4 2025 (quarter over quarter)
Kymera Therapeutics's revenue rose $31.5M (12×) from $2.9M in Q4 2025 to $34.4M in Q1 2026.
Kymera Therapeutics, Q1 2026: revenue $34.4M (+56% year over year), operating margin -244.9%, net loss $69.2M, operating cash flow −$88.8M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $34.4M | $2.9M | $31.5M | 12× |
| Other income, net | $14.9M | $10.9M | $4.0M | +37% |
| Net loss | $69.2M | $87.0M | −$17.7M | -20% |
| Costs & expenses | $119M | $101M | $17.8M | +18% |
| Operating costs | $119M | $101M | $17.8M | +18% |
| Operating cash sources | $107M | $83.2M | $23.6M | +28% |
| Depreciation & amortization | $2.0M | $2.0M | −$10K | -0.5% |
| Share-based compensation | $16.0M | $14.5M | $1.6M | +11% |
| Cash used in operations | $88.8M | $66.7M | $22.1M | +33% |
| Net loss absorbed | $69.2M | $87.0M | −$17.7M | -20% |
| Working capital & other | $37.6M | −$3.7M | $41.4M | — |
Questions
How much did Kymera Therapeutics's revenue grow quarter over quarter in Q1 2026?
Kymera Therapeutics's revenue rose $31.5M (12×) from $2.9M in Q4 2025 to $34.4M in Q1 2026.